The Correlation between Plasma Concentration of Aripiprazole and Clinical Efficacy in the Treatment of Children and Adolescent Patients with Schizophrenia-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

The Correlation between Plasma Concentration of Aripiprazole and Clinical Efficacy in the Treatment of Children and Adolescent Patients with Schizophrenia

The Correlation between Plasma Concentration of Aripiprazole and Clinical Efficacy in the Treatment of Children and Adolescent Patients with Schizophrenia

ES评分 0 浏览量：683 下载量：0

全文阅读下载引用收藏

DOI	10.20900/jpbs.20170020
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2017, 2(6)
作者	Shuzhen.Jiang*,Kun.Yan,Yonghui.Fu,Bin.Yu,Yuanjian.Yang,
作者单位	1 Department of Pharmacy, Jiangxi Mental Hospital, Nanchang 330029, China; 2 MMedical Experimental Center, Jiangxi Mental Hospital, China; 3 Department of Pediatric Psychiatry, Jiangxi Mental Hospital, China.
Abstract	Objective: To investigate the correlation between plasma drug concentration of aripiprazole and its clinical efficacy in the treatment of children and adolescent patients with schizophrenia. Methods: 27 cases of children and adolescent patients with schizophrenia received oral non-fixed dosage of aripiprazole for 8 weeks. The plasma concentration of aripiprazole was determined with High Performance Liquid Chromatography (HPLC). The psychotic symptoms of patients were evaluated with Positive and Negative Syndrome Scale (PANSS) and the adverse reactions were assessed with Treatment Emergent Symptom Scale (TESS). Results: There was no correlation between the plasma concentration of aripiprazole and the reduction rate of PANSS scores at the end of first week (r = 0.201, P > 0.05). A positive correlation between the plasma concentration of aripiprazole and the reduction rate of PANSS scores was found at the end of second week (r = 0.352, P = 0.055), and significant correlations were observed at the end of both fourth and eighth weeks (r > 0.503, P < 0.05). No relationship was found between the oral dosage of aripiprazole and the clinical efficacy. The mean concentration of aripiprazole in effective group was higher than that of ineffective group. The lowest effective concentration of aripiprazole was 285.2 ng/ml and the concentration threshold occurring side effects was 440 ng/ml. Conclusion: The plasma concentration of aripiprazole is correlated with its clinical efficacy in the treatment of children and adolescent patients with schizophrenia symptoms, and the suitable concentration range is 285.2~440 ng/ml.
KeyWord	Schizophrenia; Children and adolescent patients; Aripiprazole; plasma concentration; Clinical efficacy
基金项目
页码	-

参考文献
相关文献

1.Burd L, Kerbeshian J. A North Dakota prevalence study of schizophrenia presenting in childhood. J Am Acad Child Adolesc Psychiatry. 1987; 26:347-350.View Article

2.Thomsen PH. Schizophrenia with childhood and adolescent onset—a nationwide register-based study. Acta Psychiatr Scand. 1996; 94:187-193.View Article

3.Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in shortterm, placebo-controlled trials. Schizophr Res. 2003 Jun 1; 61(2-3):123-136.View Article

4.Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010; 32 Suppl 1:S3-20.View Article

5.Cutler AJ, Marcus RN, Hardy SA, O’Donnell A, Carson WH, McQuade RD. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr. 2006; 11:691-702.View Article

6.Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60:681-690.View Article

7.Chen X, Zheng Y.Efficacy and tolerability of aripiprazole on childhood—onset schizophrenia. Journal of Neuroscience and Mental Health. 2010; 10(1):66-68.View Article

8.Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11):1432-1441.View Article

9.Li JH, Zhong H, Shen WM, et al. Study on the relationship between the concentration of aripiprazole in the treatment of schizophrenia and the clinical effect. Chin J Clin Pharm Therap. 2011; (01):76-81.View Article

10.Lin SK, Chen CK, Liu YL. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol. 2011; 31(6):758-762.View Article

11.Zhan HY, Hu MR, Yu B, et al. Relationship between serum concentration and clinical efficacy of aripiprazole in the treatment of patients with first episode schizophrenia. Jiangxi Medical Journal. 2013; (11):958-960.View Article

12.Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004; 10(4):317-336.View Article

13.Zhou P, Liu LQ, Hao JF, et al. Study of aripiprazole in preventing hyperprolactinemia induced by antipsychotics in patients with schizophrenia. J Int Psychl. 2014; (02):68-72.View Article

引用本文

Shuzhen.Jiang*,Kun.Yan,Yonghui.Fu,Bin.Yu,Yuanjian.Yang. The Correlation between Plasma Concentration of Aripiprazole and Clinical Efficacy in the Treatment of Children and Adolescent Patients with Schizophrenia, Journal of Psychiatry and Brain Science. 2017; 2; (6). https://doi.org/10.20900/jpbs.20170020.

文献评论

相关学者

相关机构